PolyPid Ltd. (NASDAQ:PYPD) Short Interest Down 70.7% in March

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 2,700 shares, a drop of 70.7% from the February 28th total of 9,200 shares. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

PolyPid Stock Up 0.7 %

Shares of PYPD stock traded up $0.02 on Friday, reaching $2.74. 32,315 shares of the company were exchanged, compared to its average volume of 13,648. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. The company has a 50-day moving average of $2.97 and a 200-day moving average of $3.18. The company has a market cap of $27.92 million, a price-to-earnings ratio of -0.55 and a beta of 1.27. PolyPid has a one year low of $2.37 and a one year high of $5.09.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.23). Analysts anticipate that PolyPid will post -1.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

PYPD has been the topic of a number of recent analyst reports. HC Wainwright dropped their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, December 26th. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of PolyPid in a research report on Tuesday, January 28th. They set a “buy” rating and a $13.00 price objective for the company.

Hedge Funds Weigh In On PolyPid

Large investors have recently modified their holdings of the company. J. Goldman & Co LP bought a new stake in PolyPid during the 4th quarter valued at $391,000. Stonepine Capital Management LLC acquired a new position in shares of PolyPid during the third quarter valued at about $476,000. AIGH Capital Management LLC grew its holdings in shares of PolyPid by 21.8% during the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after buying an additional 148,199 shares during the last quarter. Finally, Rosalind Advisors Inc. raised its holdings in shares of PolyPid by 49.9% in the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock worth $3,095,000 after acquiring an additional 338,853 shares during the last quarter. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.